EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

IgG4 ‐to‐ IgG Ratio and Orbital Involvement Predict Clinical Response to B Cell Depletion in IgG4 ‐Related Disease

Young Min Cho iD, Alejandro Quinteros, Pallavi Khattar, Morris Clive Edelman, Lara El Khoury iD, Galina Marder

ACR Open Rheumatology · 2026-10 · 8 (10)

DOI: 10.1002/acr2.90148 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACR Open Rheumatology, online erschienen am 24.09.2026. Verfasst von Young Min Cho und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Northwell Health, New York, New York. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

IgG4‐related disease (RD) demonstrates ethnic variations in phenotype, but data from diverse US populations are limited. We characterized ethnic differences in organ involvement and evaluated predictors of treatment response in a multiethnic cohort.

Methods

We conducted a retrospective study of 58 patients meeting 2019 American College of Rheumatology/EULAR criteria at Northwell Health (2011–2023). Data on demographics, organ involvement, histopathology, treatment, and serology (IgG4‐to‐IgG ratios) were analyzed. Response was assessed using Carruthers’ Index.

Results

The cohort included 43.1% White, 24.1% Asian, 19.0% Hispanic, and 13.8% Black patients. Organ involvement patterns were consistent across races, with lymph nodes (22.4%), orbital/lacrimal (20.7%), and retroperitoneum (20.7%) being most affected. Higher disease burden was observed in Asian patients (1.93 vs 1.44–1.64 organs, P = 0.058). A striking disparity in rituximab use was observed (0% in Black patients vs 57%–76% in others, P = 0.002), whereas disease phenotype distribution was otherwise similar across groups. Favorable response rates were high and comparable across all racial and ethnic groups (78.6%–100%, P = 0.462). In patients treated with rituximab (n = 35), a reduction in IgG4‐to‐IgG ratio predicted response (area under the curve = 0.806), outperforming baseline ratios. Orbital/lacrimal involvement was strongly associated with treatment failure (75% of nonresponders vs 13.3% of responders; odds ratio 6.6, 95% confidence interval 1.4–31.9, P = 0.03).

Conclusion

In a diverse IgG4‐RD cohort, disease phenotypes were consistent across races, though treatment access disparities existed. Dynamic changes in IgG4‐to‐IgG ratios and the presence of orbital disease are key predictors of response to rituximab, informing personalized treatment strategies. image

Autor:innen und Institutionen

  • Division of Rheumatology, Northwell Health, New York, New York.
  • Department of Rheumatology Pikeville Medical Center, Pikeville, Kentucky.
  • Feinstein Institute for Medical Research, Northwell Health, New York, New York.
  • Division of Pathology, Northwell Health, New York, New York.

ORCID-Profile: Young Min Cho, Lara El Khoury

Zitieren

APA

Cho, Y. M., Quinteros, A., Khattar, P., Edelman, M. C., El Khoury, L., & Marder, G. (2026). IgG4 ‐to‐ IgG Ratio and Orbital Involvement Predict Clinical Response to B Cell Depletion in IgG4 ‐Related Disease. ACR Open Rheumatology, 8(10). https://doi.org/10.1002/acr2.90148

Vancouver

Cho YM, Quinteros A, Khattar P, Edelman MC, El Khoury L, Marder G. IgG4 ‐to‐ IgG Ratio and Orbital Involvement Predict Clinical Response to B Cell Depletion in IgG4 ‐Related Disease. ACR Open Rheumatology. 2026;8(10). doi:10.1002/acr2.90148

BibTeX
@article{Cho2026,
  author = {Cho, Young Min and Quinteros, Alejandro and Khattar, Pallavi and Edelman, Morris Clive and El Khoury, Lara and Marder, Galina},
  title = {IgG4 ‐to‐ IgG Ratio and Orbital Involvement Predict Clinical Response to B Cell Depletion in IgG4 ‐Related Disease},
  journal = {ACR Open Rheumatology},
  year = {2026},
  volume = {8},
  number = {10},
  doi = {10.1002/acr2.90148}
}
Kostenlos starten →